Download PDF
Semin Thromb Hemost 2024; 50(03): 474-488
DOI: 10.1055/s-0043-1764125
Review Article

Changes in Coagulation in Cancer Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Treatment (HIPEC)—A Systematic Review

Mikkel Lundbech
1   Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
2   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
,
Matilde Damsbo
1   Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
2   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
,
Andreas Engel Krag
2   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
3   Plastic Surgery Research Unit, Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark
,
Anne-Mette Hvas 
4   Faculty of Health, Aarhus University, Aarhus, Denmark
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Venous thromboembolism and postoperative bleeding are complications of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this systematic review was to summarize current knowledge on the effect of cytoreductive surgery with HIPEC on coagulation and fibrinolysis within 10 days after surgery. Studies were identified in PubMed, Embase, and Web of Science on December 12, 2022. Data on biomarkers of coagulation and fibrinolysis measured preoperatively up to the 10th postoperative day were extracted. Among 15 included studies, 13 studies reported markers of primary hemostasis. Eleven studies found reduced platelet count following cytoreductive surgery with HIPEC and two studies reported reduced platelet function. Twelve studies reported impaired secondary hemostasis until postoperative day 10 indicated by prolonged international normalized ratio, prothrombin time, and activated partial thromboplastin time. Fibrinogen was decreased in three studies from preoperative to postoperative day 3 switching to increased levels until postoperative day 10. In accordance, three studies found reduced maximum amplitude and maximum clot firmness by thromboelastography/thromboelastometry (ROTEM/TEG) on the first postoperative day indicating impaired clot strength. Four studies demonstrated increased d-dimer, factor (F) VIII, and thrombin generation during the 10 postoperative days. Four studies investigated fibrinolysis by ROTEM/TEG and plasminogen activator inhibitor-1 (PAI-1) after cytoreductive surgery with HIPEC reporting contradictive results. In conclusion, a decrease in platelet count and subtle changes in secondary hemostasis were found following cytoreductive surgery with HIPEC. Data on the effect of cytoreductive surgery with HIPEC on fibrinolysis are sparse and this needs to be further investigated.

Keywords

blood coagulation - hemostasis - hyperthermic intraperitoneal chemotherapy - primary tumor - operative

Supplementary Material



Publication History

Article published online:
24 February 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Verwaal VJ, van Ruth S, de Bree E. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21 (20) 3737-3743
    CrossrefPubMedGoogle Scholar
  • 2 van Driel WJ, Koole SN, Sikorska K. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; 378 (03) 230-240
    CrossrefPubMedGoogle Scholar
  • 3 Arnold M, Rutherford MJ, Bardot A. et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 2019; 20 (11) 1493-1505
    CrossrefPubMedGoogle Scholar
  • 4 Flood M, Narasimhan V, Waters P. et al. Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review and discussion of latest controversies. Surgeon 2021; 19 (05) 310-320
    CrossrefPubMedGoogle Scholar
  • 5 Kusamura S, Barretta F, Yonemura Y. et al; Peritoneal Surface Oncology Group International (PSOGI) and the French National Registry of Rare Peritoneal Surface Malignancies (RENAPE). The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg 2021; 156 (03) e206363
    CrossrefPubMedGoogle Scholar
  • 6 Abdel Mageed H, Van Der Speeten K, Sugarbaker P. The many faces of intraperitoneal chemotherapy. Surg Oncol 2022; 40: 101676
    CrossrefPubMedGoogle Scholar
  • 7 Delhorme JB, Villeneuve L, Bouché O. et al. Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). Dig Liver Dis 2022; 54 (01) 30-39
    CrossrefPubMedGoogle Scholar
  • 8 Dietz MV, van Kooten JP, Said I. et al. Survival outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with synchronous versus metachronous onset of peritoneal metastases of colorectal carcinoma. Ann Surg Oncol 2022; 29 (11) 6566-6576
    CrossrefPubMedGoogle Scholar
  • 9 Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009; 16 (08) 2152-2165
    CrossrefPubMedGoogle Scholar
  • 10 Quénet F, Elias D, Roca L. et al; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (02) 256-266
    CrossrefPubMedGoogle Scholar
  • 11 Sugarbaker PH, Alderman R, Edwards G. et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006; 13 (05) 635-644
    CrossrefPubMedGoogle Scholar
  • 12 Webb CA, Weyker PD, Moitra VK, Raker RK. An overview of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for the anesthesiologist. Anesth Analg 2013; 116 (04) 924-931
    CrossrefPubMedGoogle Scholar
  • 13 Yurttas C, Hoffmann G, Tolios A. et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med 2018; 7 (12) 567
    CrossrefPubMedGoogle Scholar
  • 14 Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15 (09) 2426-2432
    CrossrefPubMedGoogle Scholar
  • 15 Hurdle H, Bishop G, Walker A. et al. Coagulation after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective cohort analysis. Can J Anaesth 2017; 64 (11) 1144-1152
    CrossrefPubMedGoogle Scholar
  • 16 Schmidt C, Moritz S, Rath S. et al. Perioperative management of patients with cytoreductive surgery for peritoneal carcinomatosis. J Surg Oncol 2009; 100 (04) 297-301
    CrossrefPubMedGoogle Scholar
  • 17 Raspé C, Flöther L, Schneider R, Bucher M, Piso P. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol 2017; 43 (06) 1013-1027
    CrossrefPubMedGoogle Scholar
  • 18 Lundbech M, Krag AE, Iversen LH, Hvas AM. Postoperative bleeding and venous thromboembolism in colorectal cancer patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis. Int J Colorectal Dis 2022; 37 (01) 17-33
    CrossrefPubMedGoogle Scholar
  • 19 Sleightholm R, Watley D, Wahlmeier S, Patel A, Foster JM. The efficacy of dextran-40 as a venous thromboembolism prophylaxis strategy in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Am Surg 2017; 83 (02) 134-140
    CrossrefPubMedGoogle Scholar
  • 20 Vukadinovic V, Chiou JD, Morris DL. Clinical features of pulmonary emboli in patients following cytoreductive surgery (peritonectomy) and hyperthermic intraperitoneal chemotherapy (hipec), a single centre experience. Eur J Surg Oncol 2015; 41 (05) 702-706
    CrossrefPubMedGoogle Scholar
  • 21 Khan S, Kelly KJ, Veerapong J, Lowy AM, Baumgartner JM. Incidence, risk factors, and prevention strategies for venous thromboembolism after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2019; 26 (07) 2276-2284
    CrossrefPubMedGoogle Scholar
  • 22 Lanuke K, Mack LA, Temple WJ. A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Can J Surg 2009; 52 (01) 18-22
    PubMedGoogle Scholar
  • 23 Martin AS, Abbott DE, Hanseman D. et al. Factors associated with readmission after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2016; 23 (06) 1941-1947
    CrossrefPubMedGoogle Scholar
  • 24 Dranichnikov P, Mahteme H, Cashin PH, Graf W. Coagulopathy and venous thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2021; 28 (12) 7772-7782
    CrossrefPubMedGoogle Scholar
  • 25 Felder S, Rasmussen MS, King R. et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 2019; 8 (08) CD004318
    PubMedGoogle Scholar
  • 26 Lyman GH, Bohlke K, Khorana AA. et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. J Clin Oncol 2015; 33 (06) 654-656
    CrossrefPubMedGoogle Scholar
  • 27 Rottenstreich A, Kalish Y, Kleinstern G, Yaacov AB, Dux J, Nissan A. Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2017; 116 (07) 914-920
    CrossrefPubMedGoogle Scholar
  • 28 Raspe C, Piso P, Wiesenack C, Bucher M. Anesthetic management in patients undergoing hyperthermic chemotherapy. Curr Opin Anaesthesiol 2012; 25 (03) 348-355
    CrossrefPubMedGoogle Scholar
  • 29 Bell JC, Rylah BG, Chambers RW, Peet H, Mohamed F, Moran BJ. Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience. Ann Surg Oncol 2012; 19 (13) 4244-4251
    CrossrefPubMedGoogle Scholar
  • 30 Dai Y, Lee A, Critchley LA, White PF. Does thromboelastography predict postoperative thromboembolic events? A systematic review of the literature. Anesth Analg 2009; 108 (03) 734-742
    CrossrefPubMedGoogle Scholar
  • 31 Thorson CM, Van Haren RM, Ryan ML. et al. Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection. Surgery 2014; 155 (01) 134-144
    CrossrefPubMedGoogle Scholar
  • 32 Mulder MB, Proctor KG, Valle EJ, Livingstone AS, Nguyen DM, Van Haren RM. Hypercoagulability after resection of thoracic malignancy: a prospective evaluation. World J Surg 2019; 43 (12) 3232-3238
    CrossrefPubMedGoogle Scholar
  • 33 Kozek-Langenecker SA. Coagulation and transfusion in the postoperative bleeding patient. Curr Opin Crit Care 2014; 20 (04) 460-466
    CrossrefPubMedGoogle Scholar
  • 34 Kozek-Langenecker SA, Ahmed AB, Afshari A. et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 2017; 34 (06) 332-395
    CrossrefPubMedGoogle Scholar
  • 35 Kim MH, Yoo YC, Bai SJ, Lee KY, Kim N, Lee KY. Physiologic and hemodynamic changes in patients undergoing open abdominal cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Int Med Res 2021; 49 (01) 300060520983263
    CrossrefPubMedGoogle Scholar
  • 36 Tuovila M, Erkinaro T, Takala H. et al. Hyperthermic intraperitoneal chemotherapy enhances blood coagulation perioperatively evaluated by thromboelastography: a pilot study. Int J Hyperthermia 2020; 37 (01) 293-300
    CrossrefPubMedGoogle Scholar
  • 37 Teoh DA, Hutton MJH, Else S, Walker A, Lee A, Mack LA. Epidural analgesia? A prospective analysis of perioperative coagulation in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Am J Surg 2019; 217 (05) 887-892
    CrossrefPubMedGoogle Scholar
  • 38 Roy A, Stanford S, Nunn S. et al. Efficacy of fibrinogen concentrate in major abdominal surgery—a prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei. J Thromb Haemost 2020; 18 (02) 352-363
    CrossrefPubMedGoogle Scholar
  • 39 Van Poucke S, Huskens D, Van der Speeten K. et al. Thrombin generation and platelet activation in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy—a prospective cohort study. PLoS One 2018; 13 (06) e0193657
    CrossrefPubMedGoogle Scholar
  • 40 Hakeam HA, Al Duhailib Z, Salahuddin N, Amin T. Impact of tigecycline versus imipenem-cilastatin on fibrinogen levels following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a randomized-controlled study. J Chemother 2018; 30 (04) 224-232
    CrossrefPubMedGoogle Scholar
  • 41 Delhorme JB, Sattler L, Severac F. et al. Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: toward routine preoperative dosage of Von Willebrand factor?. Eur J Surg Oncol 2017; 43 (06) 1095-1101
    CrossrefPubMedGoogle Scholar
  • 42 Sargant N, Roy A, Simpson S. et al. A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Transfus Med 2016; 26 (02) 118-122
    CrossrefPubMedGoogle Scholar
  • 43 Piccioni F, Casiraghi C, Fumagalli L. et al. Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy. Int J Surg 2015; 16 (01) 99-106
    CrossrefPubMedGoogle Scholar
  • 44 Korakianitis O, Daskalou T, Alevizos L. et al. Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option. Int J Hyperthermia 2015; 31 (08) 857-862
    CrossrefPubMedGoogle Scholar
  • 45 Cooksley TJ, Haji-Michael P. Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). World J Surg Oncol 2011; 9: 169
    CrossrefPubMedGoogle Scholar
  • 46 Miao N, Pingpank JF, Alexander HR. et al. Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations. Ann Surg Oncol 2009; 16 (02) 334-344
    CrossrefPubMedGoogle Scholar
  • 47 Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M. Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia 2008; 63 (04) 389-395
    CrossrefPubMedGoogle Scholar
  • 48 Skeith L, Baumann Kreuziger L, Crowther MA, Warkentin TE. A practical approach to evaluating postoperative thrombocytopenia. Blood Adv 2020; 4 (04) 776-783
    CrossrefPubMedGoogle Scholar
  • 49 Levine EA, Votanopoulos KI, Shen P. et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg 2018; 226 (04) 434-443
    CrossrefPubMedGoogle Scholar
  • 50 Hakeam HA, Arab A, Azzam A, Alyahya Z, Eldali AM, Amin T. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Cancer Chemother Pharmacol 2018; 81 (04) 697-704
    CrossrefPubMedGoogle Scholar
  • 51 Finlay B, Price T, Hewett P. Neutropenia and thrombocytopenia after cytoreductive surgery and heated intraperitoneal chemotherapy. Pleura Peritoneum 2017; 2 (03) 137-141
    CrossrefPubMedGoogle Scholar
  • 52 Nagrebetsky A, Al-Samkari H, Davis NM, Kuter DJ, Wiener-Kronish JP. Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. Br J Anaesth 2019; 122 (01) 19-31
    CrossrefPubMedGoogle Scholar
  • 53 Sommariva A, Tonello M, Migliori E. et al. HIPEC as a risk factor for postoperative coagulopathy after cytoreductive surgery for peritoneal metastases. Updates Surg 2022; 74 (05) 1715-1723
    CrossrefPubMedGoogle Scholar
  • 54 Larsen JB, Hvas AM. Fibrinolytic alterations in sepsis: biomarkers and future treatment targets. Semin Thromb Hemost 2021; 47 (05) 589-600
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Larsen JB, Hvas AM. Fibrin clot properties in coronary artery disease: new determinants and prognostic markers. Pol Arch Intern Med 2021; 131 (11) 16113
    PubMedGoogle Scholar